{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T06:42:04Z","timestamp":1767163324562,"version":"build-2238731810"},"reference-count":119,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,31]],"date-time":"2006-01-31T00:00:00Z","timestamp":1138665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Over the last decade diagnostic techniques such as immunophenotyping as well as cytogenetic and molecular profiling gave new insights into the pathogenesis of malignant lymphoma and helped to establish the WHO classification. The recognition of well\u2010defined biological entities with distinct response and relapse patterns led to the development of more specific treatment strategies for individual lymphoma subtypes. New treatment modalities such as the monoclonal antibody rituximab have improved the results of first\u2010line treatment of patients with certain B\u2010cell lymphoma subtypes substantially. Furthermore, new prognostic factors were described for different lymphoma entities leading to further differentiation of treatment. As a consequence, the quality of relapse after first\u2010line therapy has changed and treatment strategies for relapsed disease need to be redefined. This review summarises current salvage treatment options for common lymphoma subtypes taking into account variables which should be considered before an individual patient is treated. We focus on follicular lymphoma, diffuse large B\u2010cell lymphoma and Hodgkin disease since these are most frequent and evidence\u2010based salvage strategies are beginning to emerge.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2006.05975.x","type":"journal-article","created":{"date-parts":[[2006,1,31]],"date-time":"2006-01-31T08:35:24Z","timestamp":1138696524000},"page":"3-18","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease"],"prefix":"10.1111","volume":"133","author":[{"given":"B\u00e4rbel","family":"Seyfarth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Josting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,3,2]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.12.2342"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90213-H"},{"key":"e_1_2_4_5_1","first-page":"1120a","article-title":"Allogeneic bone marrow transplantation for refractory or recurrent follicular lymphoma: a case\u2010matched analysis with autologous transplantation from the French bone marrow transplant group registry data","volume":"93","author":"Attal M.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg496"},{"key":"e_1_2_4_7_1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/oxfordjournals.annonc.a058662","article-title":"High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long term follow\u2010up in 128 patients","volume":"4","author":"Biermann P.J.","year":"1993","journal-title":"Annals of Oncology"},{"key":"e_1_2_4_8_1","first-page":"3562","article-title":"The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group","volume":"92","author":"Blay J.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.528"},{"key":"e_1_2_4_10_1","first-page":"2360","article-title":"Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia or follicular lymphoma (abstract)","volume":"90","author":"Bosch F.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_2_4_12_1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood.V60.3.693.693","article-title":"An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy","volume":"60","author":"Cabanillas F.","year":"1982","journal-title":"Blood"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.3.407"},{"key":"e_1_2_4_14_1","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood.V76.7.1293.1293","article-title":"CEPP(B): an effective and well\u2010tolerated regimen in poor risk, aggressive non Hodgkin's lymphoma","volume":"76","author":"Chao N.","year":"1990","journal-title":"Blood"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03181.x"},{"key":"e_1_2_4_16_1","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier B.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.396"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20587"},{"key":"e_1_2_4_20_1","first-page":"2269","article-title":"Retreatments with rituximab have significant efficacy, do not cause HAMA, and are a viable minimally toxic alternative in relapsed or refractory non\u2010Hodgkin's lymphoma","volume":"90","author":"Davis T.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900100203"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3920"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01666.x"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022473"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702722"},{"key":"e_1_2_4_26_1","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1182\/blood.V104.11.2483.2483","article-title":"Rituximab, gemcitabine and oxaliplatin (R\u2010GEMOX): a promising regimen for refractory\/relapsed B\u2010cell lymphoma","volume":"104","author":"El Gnaoui T.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1406"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770000163"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-90-5-761"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3128"},{"key":"e_1_2_4_33_1","first-page":"248a","article-title":"A new preparative regimen for older patients with aggressive CD 20\u2010positive B\u2010cell lymphoma utilizing standard\u2010dose yttrium\u201090 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high\u2010dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): targeted intensification without increased transplant\u2010related toxicity","volume":"102","author":"Fung H.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.572"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008294725992"},{"key":"e_1_2_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704600"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.171"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3883"},{"key":"e_1_2_4_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111283252201"},{"key":"e_1_2_4_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3264"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"},{"key":"e_1_2_4_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3837"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_4_44_1","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.V58.3.592.592","article-title":"The treatment of advanced stage favourable histology non\u2010Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy and whole body irradiation","volume":"58","author":"Hoppe R.","year":"1981","journal-title":"Blood"},{"key":"e_1_2_4_45_1","first-page":"75","article-title":"Natural history of and therapy for the indolent non\u2010Hodgkin's lymphomas","volume":"20","author":"Horning S.","year":"1993","journal-title":"Seminars in Oncology"},{"key":"e_1_2_4_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"e_1_2_4_47_1","volume-title":"World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_4_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.527"},{"key":"e_1_2_4_49_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008283909959"},{"key":"e_1_2_4_50_1","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V96.4.1280","article-title":"Prognostic factors and treatment outcome in primary progressive Hodgkin's lymphoma \u2013 a report from the German Hodgkin's Lymphoma Study Group (GHSG)","volume":"96","author":"Josting A.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_4_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.221"},{"key":"e_1_2_4_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf221"},{"key":"e_1_2_4_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi003"},{"key":"e_1_2_4_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.022"},{"key":"e_1_2_4_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.19.3918"},{"key":"e_1_2_4_56_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00960.x"},{"key":"e_1_2_4_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3911"},{"key":"e_1_2_4_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.068"},{"key":"e_1_2_4_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819042000223822"},{"key":"e_1_2_4_60_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008376728894"},{"key":"e_1_2_4_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.016"},{"key":"e_1_2_4_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0982"},{"key":"e_1_2_4_63_1","first-page":"728a","article-title":"Iodine I 131 tositumomab for patients with low\u2010grade or transformed low\u2010grade NHL: complete response data","volume":"96","author":"Leonard J.P.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_4_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.210"},{"key":"e_1_2_4_66_1","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC\u2010C2B8 (Rituximab) anti CD20 monoclonal antibody therapy in patients with relapsed low\u2010grade non\u2010Hodgkin's lymphoma","volume":"90","author":"Maloney D.G.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_4_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_4_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1262"},{"key":"e_1_2_4_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_4_70_1","first-page":"1712a","article-title":"Efficacy controls and long\u2010term follow\u2010up of patients treated with rituximab for relapsed or refractory low\u2010grade or follicular NHL","volume":"92","author":"McLaughlin P.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_4_71_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01627.x"},{"key":"e_1_2_4_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.588"},{"key":"e_1_2_4_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1291"},{"key":"e_1_2_4_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704040"},{"key":"e_1_2_4_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh406"},{"key":"e_1_2_4_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1105"},{"issue":"5","key":"e_1_2_4_77_1","article-title":"Yttrium\u201090 Ibritumomab Tiuxetan (Zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)","volume":"16","author":"Morschhauser F.","year":"2005","journal-title":"Annals of Oncology"},{"key":"e_1_2_4_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3776"},{"key":"e_1_2_4_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.616"},{"key":"e_1_2_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66659-7"},{"key":"e_1_2_4_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.05.128"},{"key":"e_1_2_4_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.3.580"},{"key":"e_1_2_4_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2095"},{"key":"e_1_2_4_84_1","article-title":"Randomized intergroup trial of first line treatment for patients <\u2003=\u200360\u2003years with diffuse large B\u2010cell non\u2010Hodgkin's lymphoma (DLBCL) with a CHOP\u2010like regimen with and without the anti\u2010CD20 antibody rituximab \u2013 early stopping after the first interim analysis","volume":"23","author":"Pfreundschuh M.G.","year":"2004","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"e_1_2_4_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_4_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.8.1039"},{"key":"e_1_2_4_87_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.437976.x"},{"key":"e_1_2_4_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.4.1050.1050"},{"key":"e_1_2_4_89_1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.V83.5.1193.1193","article-title":"Intensive therapy with cyclophosphamide, carmustine, etoposide\u2003\u00b1\u2003cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy","volume":"83","author":"Reece D.E.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_4_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-11-0107"},{"key":"e_1_2_4_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1734"},{"key":"e_1_2_4_92_1","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1182\/blood.V93.11.3632","article-title":"ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease","volume":"11","author":"Rodriguez J.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70471-8"},{"key":"e_1_2_4_94_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1177"},{"key":"e_1_2_4_95_1","first-page":"282","article-title":"Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low\u2010grade non\u2010Hodgkin's lymphoma","volume":"86","author":"Santini G.","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_4_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2615"},{"key":"e_1_2_4_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"issue":"65","key":"e_1_2_4_98_1","first-page":"R16","article-title":"Long\u2010term results of HD\u2010R1: conventional chemotherapy compared with high\u2010dose chemotherapy with autologous haemopoetic stem cell transplantation in relapsed Hodgkin's disease","volume":"73","author":"Schmitz N.","year":"2004","journal-title":"European Journal of Hematology"},{"key":"e_1_2_4_99_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2003.10.018"},{"issue":"5","key":"e_1_2_4_100_1","first-page":"67:v54","article-title":"Dose\u2010escalated CHOP plus etoposide (MegaCHOEP) followed by repeated transplantation of autologous peripheral blood stem cells in younger patients with aggressive NHL. A series of phase II studies by the German High\u2010Grade NHL Study Group","volume":"16","author":"Schmitz N.","year":"2005","journal-title":"Annals of Oncology"},{"key":"e_1_2_4_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.7.2579.2579"},{"key":"e_1_2_4_102_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_2_4_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770100321"},{"key":"e_1_2_4_104_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012551809100"},{"key":"e_1_2_4_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_4_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3842"},{"issue":"1","key":"e_1_2_4_107_1","first-page":"1461","article-title":"Non myeloablative allogeneic stem cell transplantation reduces transplant related mortality in comparison with conventional allogeneic transplantation in relapsed or refractory Hodgkin's disease: results of the European Group for Blood and Marrow Transplantation","volume":"102","author":"Sureda A.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_4_108_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265313133"},{"key":"e_1_2_4_109_1","first-page":"832","article-title":"Allogeneic bone marrow transplantation for low\u2010grade lymphoma","volume":"92","author":"Van Besien K.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_4_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1205"},{"key":"e_1_2_4_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.117.117"},{"key":"e_1_2_4_112_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1169"},{"key":"e_1_2_4_113_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290006107"},{"key":"e_1_2_4_114_1","doi-asserted-by":"crossref","first-page":"681a","DOI":"10.1182\/blood.V104.11.2482.2482","article-title":"Bendamustine\/mitoxantrone\/rituximab (BMR): a very effective and well tolerated immuno\u2010chemotherapy for relapsed and refractory indolent lymphomas \u2013 results of a multicentre phase\u2010II study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"104","author":"Weide R.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_4_115_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.8.1573"},{"key":"e_1_2_4_116_1","first-page":"411a","article-title":"Zevalin dose\u2010escalation followed by high\u2010dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplantation in non\u2010Hodgkin's lymphoma: early outcome results","volume":"100","author":"Winter J.N.","year":"2002","journal-title":"Blood"},{"key":"e_1_2_4_117_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_4_118_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"e_1_2_4_119_1","article-title":"Yttrium\u201090 ibritumomab tiuxetan radioimmunotherapy (RIT) induces durable complete responses (CR\/Cru) in patients with relapsed or refractory B\u2010cell non\u2010Hodgkin's lymphoma (NHL)","volume":"22","author":"Witzig T.E.","year":"2003","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"e_1_2_4_120_1","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting versus aggressive combined modality treatment","volume":"25","author":"Young R.C.","year":"1988","journal-title":"Seminars in Hematology"}],"updated-by":[{"DOI":"10.1111\/j.1365-2141.2006.06207.x","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T00:00:00Z","timestamp":1153180800000}}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2006.05975.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2006.05975.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T20:46:24Z","timestamp":1697402784000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2006.05975.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,2]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1111\/j.1365-2141.2006.05975.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2006.05975.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,2]]},"assertion":[{"value":"2006-03-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}